IDXX

Business Context and Reporting Period

IDEXX Laboratories, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2005. The company develops, manufactures, and distributes diagnostic products and services for the veterinary, food, and water testing markets. Operations are organized into three primary segments: the Companion Animal Group (CAG), Water testing, and the Food Diagnostics Group (FDG).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 16% to $638.1 million, driven primarily by the CAG segment (up 16%) and the FDG segment (up 28%). The Water segment grew 7%.
• Segment Performance:
  • CAG: Growth was fueled by increased sales of instruments and consumables, rapid assays, and reference laboratory services. Acquisitions in 2004 and 2005 contributed approximately 7% to CAG revenue growth.
  • FDG: Revenue surged due to higher sales of production animal products (up 42%), partly offset by a slight decline in dairy testing products.
• Profitability: While revenue grew significantly, operating income as a percentage of revenue decreased from 20% to 18%. This was attributed to acquisition integration costs, increased sales and marketing expenses, and amortization of intangible assets.
• Acquisitions: The company spent $7.6 million in 2005 to acquire veterinary reference laboratories and a digital radiography business, compared to $53.9 million in 2004.

Guidance, Outlook, and Risks

• Outlook: Management expects pharmaceutical revenue for 2006 to grow at a lower rate of 15% to 20% compared to 2005. The company anticipates that the adoption of SFAS No. 123(R) regarding share-based compensation, effective January 1, 2006, will negatively impact future gross profit percentages and operating margins.
• Key Risks:
  • Supply Chain Dependence: The company relies on single-source suppliers for critical components, including VetTest slides (Ortho), VetLyte analyzers (Roche), and VetAutoread analyzers (QBCD). Minimum purchase obligations total approximately $138.7 million through 2020.
  • Regulatory Environment: Products are subject to strict regulation by the USDA, FDA, and EPA. Failure to comply could result in product recalls or market restrictions.
  • Key Person Risk: The business relies heavily on President and CEO Jonathan W. Ayers, for whom no key man life insurance is maintained.
  • Foreign Currency: 34% of revenue is international. A 10% strengthening of the U.S. dollar could reduce operating income by approximately $2.6 million in 2006.
• Capital Allocation: The company repurchased 1.99 million shares of common stock in 2005 for $123.8 million. Approximately 2.05 million shares remain available for repurchase under the current authorization.

Investor Verification Checklist

• Supply Agreements: Verify the status and terms of the exclusive supply agreement with Ortho-Clinical Diagnostics for VetTest slides, which includes a minimum purchase commitment of $92.7 million through 2010.
• Acquisition Integration: Assess the timeline and cost impact of integrating recent acquisitions, particularly the European production animal diagnostics operations centralized in Switzerland.
• Inventory Valuation: Review the $14.4 million inventory of VetTest slides and the $9.8 million inventory related to the LaserCyte Hematology Analyzer for potential obsolescence or write-down risks.
• Share-Based Compensation: Monitor the impact of the new SFAS No. 123(R) accounting standard on 2006 earnings, as the company will begin expensing share-based compensation.
• Regulatory Approvals: Track the expansion of BSE (mad cow disease) testing programs in the U.S. and Europe, which could significantly impact the FDG segment.